International Medicine and Health Guidance News ›› 2023, Vol. 29 ›› Issue (18): 2566-2570.DOI: 10.3760/cma.j.issn.1007-1245.2023.18.012

• Thyroid Cancer • Previous Articles     Next Articles

Relationship between expressions of CCL11 and VEGF in thyroid carcinoma and pathological features

Zhang Honghong1, Li Yong2   

  1. 1 Pathology Department, Hospital Affiliated to Qingdao Binhai University, Qingdao 266500, China; 2 Pathology Department, Jining Third People's Hospital, Jining 272100, China

  • Received:2023-04-11 Online:2023-09-15 Published:2023-09-22
  • Contact: Li Yong, Email: lyong9161@163.com
  • Supported by:

    Project of Developmental Plan of Medical and Health Science and Technology in Shandong (202008021206)

甲状腺癌组织的CCL11、VEGF表达与病理特征的关系

张红红1  李涌2   

  1. 1青岛滨海学院附属医院病理科,青岛 266500;2济宁市第三人民医院病理科,济宁 272100

  • 通讯作者: 李涌,Email:lyong9161@163.com
  • 基金资助:

    山东省医药卫生科技发展计划项目(202008021206)

Abstract:

Objective To investigate the relationship between the expressions of CC chemokine ligand 11 (CCL11) and vascular endothelial growth factor (VEGF) in thyroid carcinoma and pathological features. Methods One hundred and twenty thyroid cancer tissue pathological specimens collected from Hospital Affiliated to Qingdao Binhai University from December 2020 to December 2022 and 60 benign thyroid disease tissue specimens collected during the same period were retrospectively analyzed. The 120 thyroid cancer tissue pathological specimens were set as an observation group, including 42 males and 78 females who were 25-87 (54.58±5.36) years old. The 60 benign thyroid disease tissue specimens were set as a control group, including 21 males and 39 females who were 26-86 years old. The immunohistochemical streptavidin-peroxidase (SP) method was used to detect the positive expression rates of CCL11 and VEGF. The relationship between CCL11 and VEGF on one hand and the pathological characteristics of thyroid cancer on the other hand was analyzed. χ2 test was applied. Results Compared with those in the control group, the positive expression rates of CCL11 [95.00% (114/120)] and VEGF [80.00% (96/120)] in the observation group were significantly higher (χ2=64.685 and 33.264; both P<0.05). The positive expression rates of CCL11 in the patients with Ⅲ + Ⅳ TNM stages [100.00% (48/48)], lymph node metastasis [100.00% (48/48)], and T3 + T4 depths of invasion [98.68% (75/76)] were significantly higher than those in the patients with I + Ⅱ TNM stages [91.67% (66/72)], no lymph node metastasis [91.67% (66/72)], and T1 + T2 depths of invasion [88.64% (39/44)] (χ2=4.211, 4.211, and 5.923; all P<0.05). The positive expression rates of VEGF in the patients with poorly differentiated thyroid tissue [96.43% (27/28)], Ⅲ + Ⅳ TNM stages [95.83% (46/48)], lymph node metastasis [91.67% (44/48)], T3 + T4 depths of invasion [94.74% (72/76)], and recurrence or metastasis [95.56% (43/45)] were significantly higher than those in the patients with high + moderate differentiation [75.00% (69/92)], I + Ⅱ TNM stages [69.44% (50/72)], no lymph node metastasis [72.22% (52/72)], T1 + T2 depths of invasion [54.55% (24/44)], and no recurrence or metastasis [70.67% (53/75)] (χ2=6.161, 12.535, 6.806, 28.134, and 10.889; all P<0.05). The positive expression of CCL11 in thyroid cancer tissue was positively correlated with TNM stage, lymph node metastasis, and depth of invasion (all P<0.05). The positive expression of VEGF in thyroid carcinoma was positively correlated with the degree of differentiation, TNM stage, lymph node metastasis, depth of invasion, and recurrence or metastasis (all P<0.05). Conclusions The positive expressions of CCL11 and VEGF in thyroid cancer tissue are related to pathological features, such as TNM stage, lymph node metastasis, and depth of invasion. By detecting the expression of CCL11 and VEGF, the disease severity can be effectively evaluated, so as to provide scientific references for subsequent treatment.

Key words:

Thyroid cancer tissue, CCL11, VEGF, Positive expression, Pathological features, Correlation

摘要:

目的 探讨甲状腺癌组织的嗜酸性粒细胞趋化因子(CC chemokine ligand 11,CCL11)、血管内皮生长因子(vascular endothelial growth factor,VEGF)表达与病理特征的关系。方法 采集2020年12月至2022年12月在青岛滨海学院附属医院收集的120例甲状腺癌组织病理标本及同期收集的60例正常甲状腺组织标本进行回顾性研究。将120例甲状腺癌组织病理标本设为观察组,男42例,女78例,年龄25~87(54.58±5.36)岁;将60例甲状腺良性疾病组织标本设为对照组,男21例,女39例,年龄26~86(53.66±5.65)岁。两组均采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法(streptavidin-peroxidase method,SP)检测其CCL11、VEGF表达阳性率,并分析CCL11、VEGF与甲状腺癌病理特征的关系。采用χ2检验。结果 与对照组比较,观察组的CCL11[95.00%(114/120)]、VEGF[80.00%(96/120)]阳性表达率明显更高(χ2=64.685、33.264,均P<0.05)。甲状腺组织TNM分期为Ⅲ+Ⅳ期[100.00%(48/48)]、有淋巴结转移[100.00%(48/48)]、浸润深度为T3+T4[98.68%(75/76)]的患者CCL11阳性表达率明显高于TNM分期为Ⅰ+Ⅱ期[91.67%(66/72)]、无淋巴结转移[91.67%(66/72)]、浸润深度为T1+T2[88.64%(39/44)]的患者(χ2=4.211、4.211、5.923,均P<0.05)。甲状腺组织低分化[96.43%(27/28)]、TNM分期为Ⅲ+Ⅳ期[95.83%(46/48)]、有淋巴结转移[91.67%(44/48)]、浸润深度为T3+T4[94.74%(72/76)]、有复发或转移[95.56%(43/45)]的患者VEGF阳性表达率明显高于高+中分化[75.00%(69/92)]、TNM分期为Ⅰ+Ⅱ期[69.44%(50/72)]、无淋巴结转移[72.22%(52/72)]、浸润深度为T1+T2[54.55%(24/44)]、无复发或转移[70.67%(53/75)]的患者(χ2=6.161、12.535、6.806、28.134、10.889,均P<0.05)。甲状腺癌组织CCL11阳性表达与TNM分期、淋巴结转移、浸润深度呈正相关(均P<0.05);甲状腺癌组织VEGF阳性表达与分化程度、TNM分期、淋巴结转移、浸润深度、复发或转移呈正相关(均P<0.05)。结论 甲状腺癌组织的CCL11、VEGF阳性表达与其TNM分期、淋巴结转移、浸润深度等病理特征存在一定关联。检测CCL11、VEGF的表达可有效评估患者疾病严重程度,为后续治疗提供科学的参考依据。

关键词:

甲状腺癌组织, CCL11, VEGF, 阳性表达, 病理特征, 相关性